ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
dc.contributor.author | Phongpradist, Rungsinee | |
dc.contributor.author | Chittasupho, Chuda | |
dc.contributor.author | Okonogi, Siriporn | |
dc.contributor.author | Siahaan, Teruna J. | |
dc.contributor.author | Anuchapreeda, Songyot | |
dc.contributor.author | Ampasavate, Chadarat | |
dc.contributor.author | Berkland, Cory J. | |
dc.date.accessioned | 2017-03-01T20:57:09Z | |
dc.date.available | 2017-03-01T20:57:09Z | |
dc.date.issued | 2014-10-23 | |
dc.identifier.citation | Phongpradist, Rungsinee, Chuda Chittasupho, Siriporn Okonogi, Teruna Siahaan, Songyot Anuchapreeda, Chadarat Ampasavate, and Cory Berkland. "LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery." Current Pharmaceutical Design 16.21 (2010): 2321-330. | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23320 | |
dc.description.abstract | Leukemia therapeutics are aiming for improved efficacy by targeting molecular markers differentially expressed on cancerous cells. Lymphocyte function-associated antigen-1 (LFA-1) expression on various types of leukemia has been well studied. Here, the role and expression of LFA-1 on leukemic cells and the possibility of using this integrin as a target for drug delivery is reviewed. To support this rationale, experimental results were also included where cIBR, a cyclic peptide derived from a binding site of LFA-1, was conjugated to the surface of polymeric nanoparticles and used as a targeting ligand. These studies revealed a correlation of LFA-1 expression level on leukemic cell lines and binding and internalization of cIBR-NPs suggesting a differential binding and internalization of cIBR-NPs to leukemic cells overexpressing LFA-1. Nanoparticles conjugated with a cyclic peptide against an accessible molecular marker of disease hold promise as a selective drug delivery system for leukemia treatment. | en_US |
dc.publisher | Bentham Science Publishers | en_US |
dc.subject | HL-60 cell line | en_US |
dc.subject | LFA-1 | en_US |
dc.subject | Leukemia | en_US |
dc.subject | Molt-3 cell line | en_US |
dc.subject | Molt-4 cell line | en_US |
dc.subject | Peptide | en_US |
dc.subject | Nanoparticles | en_US |
dc.subject | Targeting | en_US |
dc.subject | U937 cell line | en_US |
dc.title | LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Berkland, Cory | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
dc.identifier.doi | 10.2174/138161210791920450 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess |